75
Views
0
CrossRef citations to date
0
Altmetric
Meta-Analysis

Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials

, , , &
Pages 997-1002 | Received 18 Jan 2022, Accepted 08 Jul 2022, Published online: 21 Jul 2022

References

  • World Health Organization. [cited 2022 Jan 2]. https://covid19.who.int/
  • Lai CC, Chen CH, and Wang CY, et al. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021;76:1962–1968.
  • Lai CC, Chao CM, and Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021;54:767–775.
  • Jácome R, Campillo-Balderas JA, Ponce de León S, et al. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci Rep. 2020;10:9294.
  • Beck BR, Shin B, Choi Y, et al. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784–790.
  • Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477.
  • Jockusch S, Tao C, Li X, et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep. 2020;10(1):16577.
  • Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, et al. The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2. J Antimicrob Chemother. 2021;76:1874–1885.
  • Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75:3373–3378.
  • Abbass S, Kamal E, Salama M, et al. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: a randomized controlled trial. J Med Virol. 2021;93:6750–6759.
  • El-Bendary M, Abd-Elsalam S, and Elbaz T, et al. Efficacy of combined sofosbuvir and daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther. 2022 Feb;20(2):291–295.
  • Eslami G, Mousaviasl S, Radmanesh E, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020;75:3366–3372.
  • Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75:3379–3385.
  • Zein A, Sulistiyana CS, Raffaello WM, et al. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J. 2021. DOI:10.1136/postgradmedj-2021-14028
  • Chan HT, Chao CM, Lai CC. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: a meta-analysis. J Infect. 2021;82:e34–e5.
  • Simmons B, Wentzel H, Mobarak S, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021;76:286–291.
  • Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2021;76:753–757.
  • Mobarak S, Salasi M, Hormati A, et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother. 2021. doi:10.1093/jac/dkab433
  • Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103–112.
  • Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
  • Yadollahzadeh M, Eskandari M, Roham M, et al. Evaluation of sovodak (sofosbuvir/daclatasvir) treatment outcome in COVID-19 patient’s compared with kaletra (lopinavir/ritonavir): a randomized clinical trial. Res Square. 2021. doi:10.21203/rs.3.rs-257762/v12021
  • Yakoot M, Eysa B, Gouda E, et al. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of COVID-19: a randomized, controlled study. Preprint SSRN. 2021.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.